Mexidol® (Mexidolum®)
IM or IV (stream or drip).
When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.
Mexidol® is injected slowly over 5-7 minutes in a stream, and dropwise at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.
For acute cerebrovascular accidents
Mexidol® is used in the first 10-14 days - 200-500 mg IV drip 2-4 times a day, then 200-250 mg IM 2-3 times a day for 2 weeks.
For traumatic brain injury and consequences of traumatic brain injury
Mexidol® is used for 10-15 days intravenously at a dose of 200-500 mg 2-4 times a day.
For dyscirculatory encephalopathy in the decompensation phase
Mexidol® should be prescribed intravenously in a stream or drip at a dose of 200-500 mg 1
-
2 times a day for 14 days. Then IM 100-250 mg/day. over the next 2 weeks.
For course prophylaxis of dyscirculatory encephalopathy
the drug is administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days.
For mild cognitive impairment in elderly patients and anxiety disorders
the drug is used intramuscularly at a daily dose of 100-300 mg/day for 14-30 days.
In acute myocardial infarction as part of complex therapy
Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic agents according to indications.
In the first 5 days, to achieve maximum effect, it is advisable to administer the drug intravenously; in the next 9 days, Mexidol® can be administered intramuscularly. Intravenous administration of the drug is carried out by drip infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100-150 ml for 30-90 minutes. If necessary, a slow jet injection of the drug, lasting at least 5 minutes, is possible.
The drug is administered (intravenous or intramuscular) 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg/kg body weight per day, a single dose is 2-3 mg/kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.
For open-angle glaucoma of various stages as part of complex therapy
Mexidol® is administered intramuscularly at 100-300 mg/day, 1-3 times a day for 14 days.
For alcohol withdrawal syndrome
Mexidol® is administered in a dose of 200-500 mg intravenously or intramuscularly 2-3 times a day for 5-7 days.
In case of acute intoxication with antipsychotic drugs
the drug is administered intravenously at a dose of 200-500 mg/day for 7-14 days.
In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis)
the drug is prescribed on the first day both in the preoperative and postoperative periods. The administered doses depend on the form and severity of the disease, the prevalence of the process, and variants of the clinical course. The drug should be discontinued gradually only after a stable positive clinical and laboratory effect.
For acute edematous (interstitial) pancreatitis
Mexidol® is prescribed 200-500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly.
Mild severity of necrotizing
pancreatitis
- 100-200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly.
Moderate severity
- 200 mg 3 times a day, intravenously (in 0.9% sodium chloride solution).
Severe course
— in a pulse dosage of 800 mg on the first day, with a two-time administration regimen; then 200-500 mg 2 times a day with a gradual reduction in the daily dose.
Extremely severe course
- at an initial dosage of 800 mg/day until the manifestations of pancreatogenic shock are persistently relieved, upon stabilization of the condition, 300-500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.
MEXIDOL
Pharmacodynamics
Mexidol® is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects.
The drug increases the body's resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebrovascular accidents, intoxication with alcohol and antipsychotics (neuroleptics)). The mechanism of action of Mexidol® is due to its antioxidant, antihypoxic and membrane protective effects. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces membrane viscosity, and increases its fluidity. Mexidol® modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase),
Receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, transport of neurotransmitters and improve synaptic transmission. Mexidol® increases the content of dopamine in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition in oxidative processes in the Krebs cycle. Under hypoxic conditions, with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.
The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. Stabilizes the membrane structures of blood cells; (erythrocytes and platelets) with hemolysis. It has a lipid-lowering effect, reduces the content of total cholesterol and low-density lipoproteins.
The anti-stress effect is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.
Mexidol® has a pronounced antitoxic effect in withdrawal symptoms. It eliminates the neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, and is also able to relieve cognitive impairment caused by long-term use of ethanol and its withdrawal. Under the influence of Mexidol®, the effect of tranquilizing, neuroleptic, antidepressant, hypnotics and anticonvulsants is enhanced, which makes it possible to reduce their doses and reduce side effects. Mexidol® improves the functional state of ischemic myocardium. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium, helps maintain the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.
MEXIDOL solution for intravenous and intramuscular administration 50 mg/ml ampoule 2 ml No. 10
IM or IV (stream or drip). When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution. Mexidol® is administered in a stream slowly over 5–7 minutes, and dropwise at a rate of 40–60 drops per minute. The maximum daily dose should not exceed 1200 mg. For acute cerebrovascular accidents, Mexidol® is used in the first 10-14 days - 200-500 mg intravenously 2-4 times a day, then 200-250 mg intramuscularly 2-3 times a day for 2 weeks . For traumatic brain injury and the consequences of traumatic brain injury, Mexidol® is used for 10–15 days intravenously at a dose of 200–500 mg 2–4 times a day. For discirculatory encephalopathy in the decompensation phase, Mexidol® should be prescribed intravenously in a stream or drip at a dose of 200–500 mg 1–2 times a day for 14 days. Then IM 100–250 mg/day over the next 2 weeks. For a course of prophylaxis of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 200–250 mg 2 times a day for 10–14 days. For mild cognitive impairment in elderly patients and for anxiety disorders, the drug is used intramuscularly at a daily dose of 100–300 mg/day. for 14 – 30 days. In case of acute myocardial infarction, as part of complex therapy, Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic means according to indications. In the first 5 days, to achieve maximum effect, it is advisable to administer the drug intravenously; in the next 9 days, Mexidol® can be administered intramuscularly. Intravenous administration of the drug is carried out by drip infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100 - 150 ml for 30 - 90 minutes. If necessary, a slow jet injection of the drug, lasting at least 5 minutes, is possible. The drug is administered (intravenous or intramuscular) 3 times a day, every 8 hours. The daily therapeutic dose is 6–9 mg/kg body weight per day, a single dose is 2–3 mg/kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg. For open-angle glaucoma of various stages, as part of complex therapy, Mexidol® is administered intramuscularly at 100–300 mg/day, 1–3 times a day for 14 days. For alcohol withdrawal syndrome, Mexidol® is administered in a dose of 200–500 mg intravenously or intramuscularly 2–3 times a day for 5–7 days. In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 200–500 mg/day for 7–14 days. In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the drug is prescribed on the first day both in the preoperative and postoperative periods. The administered doses depend on the form and severity of the disease, the prevalence of the process, and variants of the clinical course. The drug should be discontinued gradually only after a stable positive clinical and laboratory effect. For acute edematous (interstitial) pancreatitis, Mexidol® is prescribed 200–500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly. Mild severity of necrotizing pancreatitis - 100 - 200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly. Moderate severity - 200 mg 3 times a day, intravenously (in 0.9% sodium chloride solution). Severe course - in a pulse dosage of 800 mg on the first day, with a two-fold administration regimen; then 200–500 mg 2 times a day with a gradual reduction in the daily dose. Extremely severe course - at an initial dosage of 800 mg/day until the manifestations of pancreatogenic shock are persistently relieved, after stabilization of the condition, 300 - 500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.
Mexidol, 10 pcs., 2 ml, 50 mg/ml, solution for intravenous and intramuscular administration
IV (stream or drip) or IM.
When administered by infusion, the drug should be diluted in an isotonic sodium chloride solution.
Mexidol® is administered slowly over 5–7 minutes in a stream, and dropwise at a rate of 40–60 drops per minute. The maximum daily dose should not exceed 1200 mg.
For acute cerebrovascular accidents
Mexidol® is used in the first 10-14 days - 200-500 mg IV drip 2-4 times a day, then - 200-250 mg IM 2-3 times a day for 2 weeks.
For TBI and consequences of TBI
- IV drip of 200–500 mg 2–4 times a day, for 10–15 days.
For dyscirculatory encephalopathy in the decompensation phase
Mexidol® should be administered intravenously in a stream or drip at a dose of 200–500 mg 1–2 times a day for 14 days. Then - IM 100-250 mg/day over the next 2 weeks.
For course prophylaxis of dyscirculatory encephalopathy
the drug is administered intramuscularly at a dose of 200–250 mg 2 times a day for 10–14 days.
For mild cognitive impairment in elderly patients and anxiety disorders
the drug is used intramuscularly at a daily dose of 100–300 mg/day for 14–30 days.
In acute myocardial infarction as part of complex therapy
Mexidol® is administered intravenously or intramuscularly for 14 days against the background of traditional therapy for myocardial infarction, including nitrates, β-blockers, ACE inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic agents according to indications. In the first 5 days, to achieve maximum effect, it is advisable to administer the drug intravenously; in the next 9 days, Mexidol® can be administered intramuscularly. The drug is administered intravenously by drip infusion, slowly (to avoid side effects) in an isotonic sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100–150 ml for 30–90 minutes. If necessary, slow jet administration of the drug is possible, lasting at least 5 minutes.
The drug is administered (IV or IM) 3 times a day, every 8 hours. The daily therapeutic dose is 6–9 mg/kg/day, a single dose is 2–3 mg/kg. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.
For open-angle glaucoma of various stages as part of complex therapy
Mexidol® is administered intramuscularly at 100–300 mg/day, 1–3 times a day for 14 days.
For alcohol withdrawal syndrome
Mexidol® is administered in a dose of 200–500 mg intravenously or intramuscularly 2–3 times a day for 5–7 days.
In case of acute intoxication with antipsychotic drugs
the drug is administered intravenously at a dose of 200–500 mg/day for 7–14 days.
In acute purulent-inflammatory processes in the abdominal cavity (acute necrotizing pancreatitis, peritonitis)
the drug is prescribed on the first day both in the preoperative and postoperative periods. The administered doses depend on the form and severity of the disease, the prevalence of the process, and variants of the clinical course. The drug should be discontinued gradually only after a stable positive clinical and laboratory effect.
For acute edematous (interstitial) pancreatitis
Mexidol® is prescribed 200–500 mg 3 times a day intravenously (in isotonic sodium chloride solution) and intramuscularly.
Mild severity of necrotizing pancreatitis
- 100–200 mg 3 times a day intravenously (in isotonic sodium chloride solution) and intramuscularly.
Moderate severity
- 200 mg 3 times a day intravenously (in isotonic sodium chloride solution).
Severe course
- in a pulse dosage of 800 mg on the first day, with a two-fold administration regimen;
then - 200–500 mg 2 times a day with a gradual reduction in the daily dose. Extremely severe course
- at an initial dosage of 800 mg/day until the manifestations of pancreatogenic shock are persistently relieved, upon stabilization of the condition - 300-500 mg 2 times a day intravenously (in isotonic sodium chloride solution) with a gradual decrease in the daily dosage.
